Skip to content
Search AI Powered

Latest Stories

What’s Going on with New York’s Legal Cannabis Roll Out? 

What's Going on With New York's Legal Cannabis Rollout
What's Going on With New York's Legal Cannabis Rollout

The New York cannabis industry is facing a complex and challenging landscape as it transitions from a medical marijuana program to a fully legal recreational market. Despite the recent legalization of adult-use cannabis in the state, there are still many issues to be addressed, including regulatory compliance, licensing, distribution, capital and equity concerns, and of course, litigation.

Recently, several lawsuits have been filed against the New York State Cannabis Control Board (CCB) and the Office of Cannabis Management (OCM), which are the agencies responsible for overseeing the state's cannabis industry.


One of the lawsuits filed in late in 2022, was brought forth by Variscite, a company registered under the laws of New York, which applied for a CAURD (Cannabis Control Board Adult-Use Retail Dispensary) license. At issue is the fact that the majority owner of Variscite had a cannabis conviction under Michigan law and no significant connection to New York, Variscite was deemed ineligible for the license. 

Variscite argued in its lawsuit that the New York residency requirement was discriminatory against out-of-state applicants and violated the Dormant Commerce Clause (DCC) implied in the Constitution. A federal judge agreed with Variscite's argument and ruled that the residency requirement did not serve a compelling state policy and, therefore, violated the DCC. During the application process, Variscite selected Brooklyn, Central New York, the Finger Lakes, the Mid-Hudson area, and Western New York as possible regions for licensure. 

Consequently, the judge ruled that New York could not issue CAURD licenses for dispensaries in those regions while the case was pending. This decision is expected to affect around 63 of the 150 CAURD licenses that the Office of Cannabis Management had planned to issue by the end of 2022. However, the ruling did not affect eleven other regions, including the Bronx, Manhattan, Queens, Staten Island, and Long Island.

Another lawsuit was recently filed by a group of larger cannabis companies, including Acreage Holdings, Columbia Care, and Curaleaf and a group of medical cannabis professionals and patients has filed a lawsuit against the state of New York, claiming that the recently passed recreational cannabis law infringes on their right to affordable and accessible medicine. The lawsuit argues that the new law, which allows for the establishment of a recreational cannabis market, will lead to shortages and increased prices for medical cannabis products. The plaintiffs contend that the state is obligated to ensure a steady supply of affordable medical cannabis products for patients, and that the new law fails to meet that obligation. 

The case highlights the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market, as more states move to legalize cannabis for both medical and recreational use.

The lawsuits come at a time when the state is still developing and finalizing its regulations for the new adult-use cannabis market. The OCM recently released its proposed rules for the industry, which include provisions aimed at promoting social equity and ensuring that small businesses have a fair shot at participating in the market.

Despite all these efforts, many stakeholders in the cannabis industry are concerned about the potential for large, out-of-state operators to dominate the market and squeeze out smaller, less capitalized local upstart businesses before they get a chance to get off the ground. They are also worried about the potential for regulatory overreach and heavy-handed enforcement.

As the state moves forward with the implementation of its new recreational cannabis market, it will need to address these and a host of other concerns in order to create a fair and equitable industry that benefits all stakeholders, from large corporations to small businesses and individual consumers. 

The lawsuits filed against the CCB and OCM are just one indication of the complex and challenging landscape that lies ahead for New York's nascent legal cannabis industry.

And, the response from across the New York cannabis industry has been mixed. Some industry leaders argue that the lawsuits are misguided and that the new laws will ultimately benefit medical cannabis patients by increasing overall demand for cannabis products and driving down prices. Others, however, acknowledge that there may be some short-term disruptions as the recreational market ramps up, and they urge the state government to take steps to ensure that medical cannabis patients are not unduly affected.

Overall, the lawsuits highlight the complex and sometimes competing interests at play in the expanding cannabis industry, as well as the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market and those interested in building an equitable and fair industry for those communities most directly impacted by the war on drugs. 

As more states legalize cannabis for both medical and recreational use, similar issues are likely to arise, and policymakers will need to not only carefully consider the impact of their decisions on all stakeholders involved, but to actually invest the time and resources in listening to each of these stakeholders and involving them in decision making process. 

Overall, the development of NY’s nascent cannbis market to a mature cannabis market is going to be a complex and dynamic process that will require careful attention to changing market conditions, industry, consumer and patient needs and regulatory requirements. 

We have to remember that we are still in the first inning of this and we will see NY’s legal cannabis industry thriving in the coming months, lawsuits and all. We’re NYers after all and we don’t let much, if anything, stand in our way. 

As Alicia Keys so soulfully sings: 

Even if it ain't all it seems

We got a pocketful of dreams 

Baby, we’re from New York

Concrete jungle where dreams are made of

There's nothin' we can't do

Now, we’re in New York

These streets will make us feel brand-new

Now, let’s hear it for New York, New York, New York

More For You

OCM Alleges 'Rent-a-License' Scheme, Seeks License Revocation
OCM Alleges 'Rent-a-License' Scheme, Seeks License Revocation
Photo by Jon Tyson on Unsplash

NY Revokes License in Rent-a-License Scam

At-a-Glance

  • What’s new: NY’s Office of Cannabis Management (OCM) issued a Notice of Pleading (NOP) charging Omnium Health (d/b/a Omnium Canna) with facilitating unlicensed production under its license and ordered a statewide retail recall tied to products made by unlicensed processors.
  • Why it matters: Regulators call it “reverse licensing” - unlicensed operators allegedly producing/packaging cannabis under a licensee’s umbrella, which undermines market integrity and fairness.
  • Penalties sought: License revocation (processor + distributor), debarment from future licensure, civil penalties tied to projected revenue, and destruction of unlawfully made products.
  • Timeline: Investigation began February 2025; OCM announcement issued October 20, 2025; coverage followed October 22, 2025.

What Exactly Is OCM Alleging?

OCM says Omnium let unlicensed businesses use its facilities and resources, and charged them rent, creating a “rent-a-license” (aka “reverse licensing”) arrangement. Investigators cite contracts, audits, and witness testimony supporting the claim.

The NOP also points to seized materials, including unlabeled THCA isolate (no batch IDs or traceability) and packaging labeled “Omnium d/b/a MFused,” which investigators say reflected space and license rental.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less
gif of actor Kevin James from King of Queens; asking "How Much Does That Cost?"
Why Is Some Weed More Expensive Than Others? Understanding Cannabis Pricing
Giphy

Unraveling Cannabis Pricing: Factors Behind the Cost of Weed


Step inside a cannabis dispensary for the first time and the experience can be overwhelming. The meticulously labeled glass jars showcase dozens of strains with names like "Wedding Cake" and "Blue Dream," while refrigerated cases display concentrates, edibles, and tinctures at wildly different price points. Unlike the days when consumers were limited to whatever their neighborhood dealer offered, today's legal market presents a dazzling array of options that might leave newcomers with both wonder and sticker shock.

Keep ReadingShow less
Hall of Flowers NYC 2025: Cali Vibes Minus the Pulse of NY Cannabis

Hall of Flowers NYC Debut: Cali Vibes Minus the Pulse of NY Cannabis

Photo courtesy of Hall of Flowers

Hall of Flowers NYC 2025: Cali Vibes Minus the Pulse of NY Cannabis

Upon entering through the doors at Pier 36 it was refreshing to see row after row of identical booths, neat as a spreadsheet, designed to let the product speak for itself. Buyers drifted through the aisles with line sheets instead of selfie sticks, the volume dialed way down compared to last month's Revelry event at the same location. And, maybe that was the point. Hall of Flowers’ first New York edition was designed for commerce, not commotion: a buyers-only opening day, tight credentialing, a controlled environment and pace that favored real conversations over spectacle.

The uniformity of Hall of Flowers' format erased the booth-flex arms race; most of the brands stood shoulder-to-shoulder on product, pricing, and execution. “Much easier to have conversations here than at Revelry,” several attendees told us. Others called it “weak” or “quiet” by comparison. One marketing exec involved in the event went all in saying, “Revelry is a flea market compared to Hall of Flowers.” What he meant by that is: Hall of Flowers is a curated, high-end trade event, whereas Revelry functions more as a community marketplace. I could see his point.

Keep ReadingShow less
Lights, Camera, Cannabis: The New Theater Experience
Cigar smoking in a bar....
Giphy

NY Movie Theaters: High on Cannabis Lounges

In the dimly lit ambiance of New York City's historic movie theaters, the scent of buttered popcorn has long been the olfactory hallmark. However, as cannabis legalization sweeps across the state, a provocative question emerges: Could the future of cinema include the aroma of cannabis alongside the traditional concessions?

The Current Landscape of Cannabis Consumption Lounges

New York State’s Clean Indoor Air Act (CIAA) casts a long shadow over this budding idea. Enacted to safeguard public health, the CIAA prohibits smoking and vaping in most indoor workplaces, encompassing bars, restaurants, and, notably, movie theaters. The act defines smoking expansively, including the burning of tobacco, cannabis, or cannabinoid-hemp products. Violations can result in fines up to $2,000 for each infraction, underscoring the state’s commitment to maintaining smoke-free public spaces.

Keep ReadingShow less